Carolina Moraes

Mrs. Carolina Moraes

Oswaldo Cruz Institute/Fiocruz
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2014 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
CMCarolina Moraes
Carolina Moraes
GSGabriel Santos
Gabriel Santos
TSTania Cristina Leite de Sampaio e Spohr
Tania Cristina Leite de Sampaio e Spohr
JDJoana C. D’avila
Joana C. D’avila
FLFlavia Regina Souza Lima
Flavia Regina Souza Lima
FGFlávia Carvalho Alcantara Gomes
Flávia Carvalho Alcantara Gomes

1 May 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CMCarolina Moraes
Carolina Moraes
CVCamila Valle
Camila Valle
RFRenaud Fleurance
Renaud Fleurance
TSTarek Sharshar
Tarek Sharshar
FBFernando Bozza
Fernando Bozza
Joana D'AvilaJoana D'Avila
Joana D'Avila
Frequently underestimated, encephalopathy or delirium are common neurological manifestations associated with sepsis. Brain dysfunction occurs in up to 80% of cases and is directly associated with increased mortality and long-term neurocognitive consequences. Although the central nervous system (CNS) has been classically viewed as an immune-privileged system, neuroinflammation is emerging as a central mechanism of brain dysfunction in sepsis. Microglial cells are major players in this setting. Here, we aimed to discuss the current knowledge on how the brain is affected by peripheral immune activation in sepsis and the role of microglia in these processes. This review focused on the molecular pathways of microglial activity in sepsis, its regulatory mechanisms, and their interaction with other CNS cells, especially with neuronal cells and circuits.

21 November 2014 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
JSJoice Stipursky
Joice Stipursky
DFDaniel Francis
Daniel Francis
RDRomulo Sperduto Dezonne
Romulo Sperduto Dezonne
AAAna Paula Bã©Rgamo de Araãºjo
Ana Paula Bã©Rgamo de Araãºjo
LSLays Souza
Lays Souza
FGFlávia Carvalho Alcantara Gomes
Flávia Carvalho Alcantara Gomes
The major neural stem cell population in the developing cerebral cortex is composed of the radial glial cells, which generate glial cells and neurons. The mechanisms that modulate the maintenance of the radial glia stem cell phenotype, or its differentiation, are not yet completely understood. We previously demonstrated that the transforming growth factor-β1 (TGF-β1) promotes radial glia differentiation into astrocytes in vitro (Glia 2007; 55:1023-33) through activation of multiple canonical and non-canonical signaling pathways (Dev Neurosci 2012; 34:68-81). However, it remains unknown if TGF-β1 acts in radial glia-astrocyte differentiation in vivo. Here, we addressed the astrogliogenesis induced by TGF-β1 by using the intraventricular in utero injection in vivo approach. We show that injection of TGF-β1 in the lateral ventricles of E14,5 mice embryos resulted in radial glia fibers disorganization and premature gliogenesis, evidenced by appearance of GFAP positive cells in the cortical wall. These events were followed by decreased numbers of neurons in the cortical plate. Together, we also described that TGF-β1 actions are region-dependent, once radial glia cells from dorsal region of the cerebral cortex demonstrated to be more responsive to this cytokine compared with radial glia from lateral cortex either in vitro as well as in vivo. Our work demonstrated that TGF-β1 is a critical cytokine that regulates radial glia fate decision and differentiation into astrocytes in vitro and in vivo. We also suggest that radial glia cells are heterogeneous population that acts as distinct targets of TGF-β1 during cerebral cortex development.

25 October 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
CMCarolina Moraes
Carolina Moraes
EHEugenio DAMACENO Hottz
Eugenio DAMACENO Hottz
DODébora Dos Santos Ornellas
Débora Dos Santos Ornellas
DADaniel Adesse
Daniel Adesse
CACarolina T. de Azevedo
Carolina T. de Azevedo
FBFernando Bozza
Fernando Bozza

1 April 2020 in Critical Care Medicine
Verified
Journal Article
Closed access
ASAdriano Y. O. Bs Silva
Adriano Y. O. Bs Silva
ÉAÉrica A. Bsc Amorim
Érica A. Bsc Amorim
MBMaria C. Msc Barbosa-Silva
Maria C. Msc Barbosa-Silva
MLMaiara N. Msc Lima
Maiara N. Msc Lima
HOHelena A. Oliveira
Helena A. Oliveira
TMTatiana Maron-Gutierrez
Tatiana Maron-Gutierrez
Objectives: Survivors of sepsis are frequently left with significant cognitive and behavioral impairments. These complications derive from nonresolving inflammation that persists following hospital discharge. To date, no study has investigated the effects of mesenchymal stromal cell therapy on the blood-brain barrier, astrocyte activation, neuroinflammation, and cognitive and behavioral alterations in experimental sepsis. Design: Prospective, randomized, controlled experimental study. Setting: Government-affiliated research laboratory. Subjects: Male Swiss Webster mice (n = 309). Interventions: Sepsis was induced by cecal ligation and puncture; sham-operated animals were used as control. All animals received volume resuscitation (1 mL saline/mouse subcutaneously) and antibiotics (meropenem 10 mg/kg intraperitoneally at 6, 24, and 48 hours). Six hours after surgery, mice were treated with mesenchymal stromal cells IV (1 × 105 cells in 0.05 mL of saline/mouse) or saline (0.05 mL IV). Measurements and Main Results: At day 1, clinical score and plasma levels of inflammatory mediators were increased in cecal ligation and puncture mice. Mesenchymal stromal cells did not alter clinical score or survival rate, but reduced levels of systemic interleukin-1β, interleukin-6, and monocyte chemoattractant protein-1. At day 15, survivor mice completed a battery of cognitive and behavioral tasks. Cecal ligation and puncture mice exhibited spatial and aversive memory deficits and anxiety-like behavior. These effects may be related to increased blood-brain barrier permeability, with altered tight-junction messenger RNA expression, increased brain levels of inflammatory mediators, and astrogliosis (induced at day 3). Mesenchymal stromal cells mitigated these cognitive and behavioral alterations, as well as reduced blood-brain barrier dysfunction, astrocyte activation, and interleukin-1β, interleukin-6, tumor necrosis factor-α, and interleukin-10 levels in vivo. In cultured primary astrocytes stimulated with lipopolysaccharide, conditioned media from mesenchymal stromal cells reduced astrogliosis, interleukin-1β, and monocyte chemoattractant protein-1, suggesting a paracrine mechanism of action. Conclusions: In mice who survived experimental sepsis, mesenchymal stromal cell therapy protected blood-brain barrier integrity, reduced astrogliosis and neuroinflammation, as well as improved cognition and behavior.